Does Immunotherapy Have a Role in the Management of Endometriosis?
试验速览
- 阶段
- 不适用
- 入组人数
- 40
- 主要终点
- immunohistochemical staining
研究概览
简要总结
Pathological specimens of 40 women that had been operated for endometriosis will be included in this study. These tissues will be stained with a marker named as PDL-1 in pathological examination. "programmed cell death (PD-1)" is expressed on T cells. The immunotherapies in which antibodies against these PD-1 and its ligands (PDL-1) have been used are accepted as very effective in the treatment of many cancers. If these ligands can be shown in the endometriosis, it will be an important step for the treatment of endometriosis.
详细描述
40 women who had been operated for endometriosis between 2013 and 2014 will be included in this study. Pathological specimens will be stained with an immunohistochemical marker named as PDL-1. "programmed cell death (PD-1)" is a protein containing 288 aminoacids and expressed on T cells. It was shown on apoptotic cells in earlier times, but then it has been understood that its physiologic role is not cell death. The upregulation of PD-1 is a result of the activation of T cells and it is necessary for the termination of immune response. PD-L1 is a ligand for PD-1. The immunotherapies in which antibodies against these PD-1 and its ligands (especially PDL-1) provides significant improvements in many cancers such as melanoma. Evidence about the role of these ligands in endometriosis will be an important step in its management.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •patients operated for endometriosis between 2013 and 2014
- •pathological examinations proving the diagnosis of endometriosis
排除标准
- •patients operated for cysts other than endometriosis
结局指标
主要结局
immunohistochemical staining
时间窗: 6 months
immunohistochemical staining with PD-L1
次要结局
未报告次要终点
研究者
Hale GOKSEVER CELIK
Principal investigator
Kanuni Sultan Suleyman Training and Research Hospital